Strain Engineering And Process Development: A Commercially Proven Platform For Biopharmaceutical Manufacturing

Early-stage decisions in therapeutic protein development, particularly around host cell selection and gene expression strategy, have an outsized effect on downstream manufacturability and cost. Many programs stall because initial process development evaluates too narrow a range of expression conditions, producing low titers or inconsistent quality. A microbial expression platform built on Pseudomonas fluorescens, combined with automated parallel strain construction and screening, addresses this directly. By evaluating a broad design space simultaneously, developers can identify high-performing strains earlier and carry forward candidates with demonstrated yield and quality attributes, rather than discovering process limitations late in development.

This approach has been validated across multiple commercial biologics, demonstrating that platform-based strain engineering is not theoretical but operationally proven at scale. Read the full article to learn more.